A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)

What Was Tested

This registered phase 4 trial tested Tirzepatide.

The main purpose of this study is to investigate the effects of switching from glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy to tirzepatide glucose-dependent insulinotropic polypeptide (GIP) GLP-1 RA agonist in participants with type 2 diabetes (T2D).

The registry classes the interventions as drug.

Who Took Part

152 actual participants took part.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Have Type 2 diabetes (T2D). Have a body mass index (BMI) ≥25 kilogram per square meter (kg/m²) at screening.

The full record lists 5 inclusion and 16 exclusion criteria; among the exclusions: have type 1 diabetes (t1d); have a clinical history of; proliferative diabetic retinopathy.

How the Study Was Run

It was run as a single-group and open-label study.

Nothing was hidden in this open-label Tirzepatide study: the participants and staff both knew the treatment.

Everyone received the same intervention, so there was no separate comparison group inside the trial.

It started in 2023-03-08 with completion listed for 2023-10-31.

It ran at 32 sites in United States (32).

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): Change From Baseline in Hemoglobin A1c (HbA1c) (time frame: Baseline, Week 12).

It also tracked 6 secondary outcomes, for example Change From Baseline in Fasting Serum Glucose (FSG) and Change From Baseline in Weight.

What This Means in Plain Language

Put simply, this is a phase 4 trial of Tirzepatide in 152 people.

The trial is marked completed; results are posted on the registry, and this page does not restate them.

More context: the Tirzepatide compound page, all human trials.